@FierceBiotech: Shire pays a steep premium to nab ViroPharma in $4.2B deal. More | Follow @FierceBiotech
@JohnCFierce: Just a few weeks ago Zalicus ($ZLCS) did a 6 for one reverse split to get its stock price back into compliance. Oh well. | Follow @JohnCFierce
@DamianFierce: Still-blazing IPO market takes Ultragenyx from "next year" to "right now." News | Follow @DamianFierce
@EmilyMFierce: Japanese Global Health Innovative Technology Fund awards $5.7M in grants for infectious disease vaccine work. Story | Follow @EmilyMFierce
> Novartis ($NVS) has in-licensed ImmunoGen's antibody-drug conjugate technology for its oncology group. Release
> Alexion Pharmaceuticals ($ALXN) presented data from four clinical trials demonstrating the benefit of using Soliris to treat atypical hemolytic uremic syndrome, an ultra-rare disease associated with organ failure and premature death. Release
> Texas-based ZS Pharma, which last year raised a $46 million venture round, says that ZS-003 met its primary endpoint in a Phase III study for hyperkalemia. Release
@FierceMedDev: Pfizer, marketing partner pay MA fine for ad overstating EpiPen's benefits. More | Follow @FierceMedDev
@MarkHFierce: Novartis is unloading its blood transfusion Dx unit for more than $1.6B PR. Article | Follow @MarkHFierce
@MichaelGFierce: ICYMI: Chinese investors pursue groundbreaking med tech from Canada's MDI. Story | Follow @MichaelGFierce
> Topera rolls out next-gen heart imaging tech in wake of U.S., EU sign-offs. Story
> TB Dx maker Oxford Immunotec prices IPO shares. More
> FDA report: Intuitive's robots beneficial, but training still lacking. News
Pharma News
@FiercePharma: Best-read special report this weekend: Top 10 Patent Losses for 2014. Report | Follow @FiercePharma
@CarlyHFierce: Rare-disease co. ViroPharma finally snatched up after lots of speculation--Shire gets it for $4.2B. Release | Follow @CarlyHFierce
> FDA slaps Aegerion for CEO's fast-and-loose interviews with CNBC. Story
> AstraZeneca to build £120 million U.K. plant. News
> Novartis hives off blood diagnostics for $1.7B in first slim-down sale. Article
CRO News
> Cel-Sci demands $50M from inVentiv over alleged trial fraud. More
> Quintiles paid $146.5M for Novella. Article
> Capsugel bets $20M on Bend's commercial manufacturing. Story
> AMRI steers clear of FDA warning letter after years of fixes. Piece
> Covance partners up for biologics safety testing. Story
Biotech IT News
> Scientists increasingly receptive to life science vendors on social media. News
> Open-access genomics database causes hand-wringing in U.K. More
> Catalent creates web-based tool to ease drug delivery tech selection. Story
> BioDatomics pitches open-source, freemium bioinformatics package. Piece
> Advocacy groups crowdsourcing patient views on risk-benefit of drugs. News